Article in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 2 institutions in 1 country.
Karin Melanie Cabanillas Stanchi *Department of General Pediatrics, Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-7669-9159
Semjon Willier *Department of Pediatric Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Dr. Von Hauner Children's Hospital, University Hospital, LMU, Munich, Germany.
Julia VekDepartment of General Pediatrics, Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.
Patrick SchlegelDepartment of General Pediatrics, Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.
Manon QueudevilleDepartment of General Pediatrics, Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-5642-1846
Nora RieflinDepartment of General Pediatrics, Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-4792-7837
Veronika KlausDepartment of General Pediatrics, Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-2967-7790
Melanie GanselDepartment of General Pediatrics, Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-7500-5987
Joachim Vincent RupprechtDepartment of General Pediatrics, Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.
Tim FlaadtDepartment of General Pediatrics, Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.
Vera BinderDepartment of Pediatric Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Dr. Von Hauner Children's Hospital, University Hospital, LMU, Munich, Germany.
Tobias FeuchtingerDepartment of Pediatric Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Dr. Von Hauner Children's Hospital, University Hospital, LMU, Munich, Germany.ORCID 0000-0002-8517-9681
Peter LangDepartment of General Pediatrics, Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.
Rupert HandgretingerDepartment of General Pediatrics, Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.
Michaela DöringDepartment of General Pediatrics, Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-8134-7350
University Children's Hospital Tübingen · DELudwig-Maximilians-Universität München · DE
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundHigh-dose myeloablative conditioning prior to autologous hematopoietic stem cell transplantation (autoHSCT) in pediatric patients is usually highly emetogenic. The antiemetic neurokinin-1 receptor antagonist fosaprepitant was safe and effective in children receiving highly emetogenic chemotherapy. Data on fosaprepitant during autoHSCT in children are currently not available.
methodsA total of 35 consecutive pediatric patients, who received an antiemetic prophylaxis with fosaprepitant (4 mg/kg; single dose, max. 1 x 150 mg/kg BW) and ondansetron (24-hours continuous infusion; 8-32 mg/24h) or granisetron (2 x 40 µg/kg∙d
resultsClinical adverse events and clinically relevant increases/decreases of laboratory markers were similarly low and did not significantly differ between the two study groups (
conclusionThe fosaprepitant-based antiemetic prophylaxis was safe, well tolerated and significantly reduced vomiting in children undergoing highly emetogenic chemotherapy prior to autoHSCT. Prospective randomized trials are necessary to confirm these results.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Antiemetic Prophylaxis with Fosaprepitant and 5-HT · full record | Socratic